Menu Close

Lecanemab: Experimental drug is a ray of hope for Alzheimer’s disease

On Nov. 30, Eisai and Biogen announced the results of their latest phase 3 clinical trial in Alzheimer’s disease. The verdict: an 18-month treatment with lecanemab slows functional and cognitive loss by 27 percent in people with mild cognitive impairment or mild dementia due to Alzheimer’s disease. The study results were also published in the New England Journal of Medicine.